Abstract
Melanoma is the deadliest form of skin cancer being responsible for 80% of skin cancer deaths. Furthermore, the incidence of metastatic melanoma has increased over the past three decades with a mortality rate that continues to rise faster than most of all other cancers. The last few years have witnessed an unparalleled change in treatment options for patients with metastatic melanoma by the development of new therapeutic strategies like targeted therapies and immunotherapies that highly improved the patient’s prognosis. Despite the paradigm- shifting success of these novel treatments, their effectiveness is still limited by intrinsic or acquired resistance. The objective of this review is to provide an overview of the new available treatment modalities, criteria to select patients who might benefit from a specific therapy, mechanisms of innate and acquired resistance to these treatments and to discuss strategies to overcome drug resistance.
Keywords: Melanoma, chemotherapy, drug resistance, immunotherapy, targeted-therapies, BRAF, MEK.
Current Pharmaceutical Design
Title:The Emerging Therapeutic Landscape of Advanced Melanoma
Volume: 24 Issue: 5
Author(s): Vanessa Henriques, Teresa Martins, Wolfgang Link and Bibiana I. Ferreira*
Affiliation:
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro,Portugal
Keywords: Melanoma, chemotherapy, drug resistance, immunotherapy, targeted-therapies, BRAF, MEK.
Abstract: Melanoma is the deadliest form of skin cancer being responsible for 80% of skin cancer deaths. Furthermore, the incidence of metastatic melanoma has increased over the past three decades with a mortality rate that continues to rise faster than most of all other cancers. The last few years have witnessed an unparalleled change in treatment options for patients with metastatic melanoma by the development of new therapeutic strategies like targeted therapies and immunotherapies that highly improved the patient’s prognosis. Despite the paradigm- shifting success of these novel treatments, their effectiveness is still limited by intrinsic or acquired resistance. The objective of this review is to provide an overview of the new available treatment modalities, criteria to select patients who might benefit from a specific therapy, mechanisms of innate and acquired resistance to these treatments and to discuss strategies to overcome drug resistance.
Export Options
About this article
Cite this article as:
Henriques Vanessa, Martins Teresa, Link Wolfgang and Ferreira I. Bibiana*, The Emerging Therapeutic Landscape of Advanced Melanoma, Current Pharmaceutical Design 2018; 24 (5) . https://dx.doi.org/10.2174/1381612824666180125093357
DOI https://dx.doi.org/10.2174/1381612824666180125093357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) The Prominent Role of Protein-Based Delivery Systems on the Development of Cancer Treatment
Current Pharmaceutical Design Alkaloid-Metal Based Anticancer Agents
Current Topics in Medicinal Chemistry Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Current Pharmaceutical Design Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Current Signal Transduction Therapy Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews Piperidin-4-one: The Potential Pharmacophore
Mini-Reviews in Medicinal Chemistry Hypoxia and Fetal Heart Development
Current Molecular Medicine Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Training Pediatric Residents for Intervention on Tobacco
Current Pediatric Reviews Determination of Binding Constant and Stoichiometry for Antibody-Antigen Interaction with Surface Plasmon Resonance
Current Proteomics Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Polo-Like Kinases Inhibitors
Current Medicinal Chemistry Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Alcohol Addiction: A Molecular Biology Perspective
Current Medicinal Chemistry